Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 2.350-2.650 for the period, compared to the consensus earnings per share estimate of 2.540. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Teva Pharmaceutical Industries also updated its Q1 2025 guidance to 0.520-0.520 EPS.

Wall Street Analyst Weigh In

Several research analysts have commented on TEVA shares. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 1.2 %

TEVA stock opened at $15.50 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business’s 50 day moving average price is $17.35 and its two-hundred day moving average price is $18.14. The company has a market capitalization of $17.57 billion, a price-to-earnings ratio of -10.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.